KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Average (2016 - 2025)

Historic Equity Average for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to $48.8 million.

  • Pacific Biosciences Of California's Equity Average fell 8968.32% to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year decrease of 8968.32%. This contributed to the annual value of $603.9 million for FY2024, which is 445.42% down from last year.
  • Per Pacific Biosciences Of California's latest filing, its Equity Average stood at $48.8 million for Q3 2025, which was down 8968.32% from $76.6 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Equity Average registered a high of $815.9 million during Q4 2021, and its lowest value of $48.8 million during Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $594.7 million (2022), whereas its average is $527.2 million.
  • Per our database at Business Quant, Pacific Biosciences Of California's Equity Average surged by 54314.17% in 2021 and then tumbled by 8968.32% in 2025.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Equity Average stood at $815.9 million in 2021, then fell by 27.11% to $594.7 million in 2022, then grew by 23.17% to $732.5 million in 2023, then crashed by 34.49% to $479.9 million in 2024, then plummeted by 89.83% to $48.8 million in 2025.
  • Its Equity Average stands at $48.8 million for Q3 2025, versus $76.6 million for Q2 2025 and $299.1 million for Q1 2025.